1-[1-[4-[[7-(1-methylpyrazol-4-yl)quinazolin-2-yl]amino]phenyl]-1,2,4-triazol-3-yl]piperidin-3-ol
C25H25N9O — CID 117078519
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[1-[4-[[7-(1-methylpyrazol-4-yl)quinazolin-2-yl]amino]phenyl]-1,2,4-triazol-3-yl]piperidin-3-ol
1-[1-[4-[[7-(1-methylpyrazol-4-yl)quinazolin-2-yl]amino]phenyl]-1,2,4-triazol-3-yl]piperidin-3-ol (PubChem CID 117078519) has the molecular formula C25H25N9O and a molecular weight of 467.54 g/mol. Its IUPAC name is 1-[1-[4-[[7-(1-methylpyrazol-4-yl)quinazolin-2-yl]amino]phenyl]-1,2,4-triazol-3-yl]piperidin-3-ol.
Molecular Properties
| Compound Name | 1-[1-[4-[[7-(1-methylpyrazol-4-yl)quinazolin-2-yl]amino]phenyl]-1,2,4-triazol-3-yl]piperidin-3-ol |
|---|---|
| PubChem CID | 117078519 |
| Molecular Formula | C25H25N9O |
| Molecular Weight | 467.54 g/mol |
| Exact Mass | 467.22 |
| IUPAC Name | 1-[1-[4-[[7-(1-methylpyrazol-4-yl)quinazolin-2-yl]amino]phenyl]-1,2,4-triazol-3-yl]piperidin-3-ol |
| SMILES | Cn1cc(-c2ccc3cnc(Nc4ccc(-n5cnc(N6CCCC(O)C6)n5)cc4)nc3c2)cn1 |
| InChI | InChI=1S/C25H25N9O/c1-32-14-19(13-28-32)17-4-5-18-12-26-24(30-23(18)11-17)29-20-6-8-21(9-7-20)34-16-27-25(31-34)33-10-2-3-22(35)15-33/h4-9,11-14,16,22,35H,2-3,10,15H2,1H3,(H,26,29,30) |
| InChIKey | GVNVLCKJBUUHQJ-UHFFFAOYSA-N |
| XLogP | 3.32 |
| TPSA | 109.81 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 467.54 |
| LogP ≤ 5 | 3.32 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 117078519 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.